Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with virus-specific T cells:
A phase III, prospective, multi-national clinical trialTRACE is the first multi-national clinical trial to prove efficacy and safety of Adoptive T-cell transfer in immunocompromised individuals. Until now, 181 out of 246 (74%) patients with various viral diseases have been successfully treated with virus-specific T-cells. TRACE will provide data, ethical and regulatory approvals and logistic infrastructure to build the basis for bringing adoptive transfer of virus-specific T-cells into clinical routine.